gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1088-1093

  Sirgel, Frederick A ^a   Warren, Robin M ^a   Streicher, Elizabeth M ^a   Victor, Thomas C ^a   Van helden, Paul D ^a   Böttger, Erik C ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Fluoroquinolones; In vitro activity; Susceptibility testing

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIUM ISOLATE; CODON; DNA SEQUENCE; GENE MUTATION; GENETIC SUSCEPTIBILITY; LIMIT OF QUANTITATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES;

EID: 84859565524     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks033     Document Type: Article

References (28)

1. WHO. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. WHO/HTM/TB/2008.392. Geneva: WHO, 2008; 1-20. http://www.who.int/tb/publications/2008/whohtmtb_ 2008_392/en/index.html (12 January 2012, date last accessed).
2. Jacobson KR, Tierney DB, Jeon CY et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
3. Krüüner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-8.
4. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-42.
5. Crowle AJ, Elkins N, May MH. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 1988; 137: 1141-6.
6. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO/HTM/TB/2008.402. Geneva: WHO, 2008; 1-247. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf (17 January 2012, date last accessed).
7. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001; 32 Suppl 1: 16-22.
8. Pestova E, Millichap JJ, Noskin GA et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000; 45: 583-90.
9. Kam KM, Yip CW, Cheung TL et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006; 12: 7-11.
10. Poissy J, Aubry A, Fernandez C et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765-71.
11. Von Groll A, Martin A, Jureen P et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-500.
12. Öngeby KA, Jureen P, Giske CG et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010; 65: 946-52.
13. Gillespie SH, Basu S, Dickens AL et al. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 2005; 56: 344-8.
14. Shi R, Zhang J, Li C et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006; 44: 4566-8.
15. Cox HS, McDermid C, Azevedo V et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One 2010; 5: e13901.
16. van Embden JD, Cave MD, Crawford JT et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-9.
17. Kamerbeek JL, Schouls A, Kolk A et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-14.
18. Streicher EM, Victor TC, van der Spuy G et al. Spoligotype signatures in theMycobacterium tuberculosis complex. J Clin Microbiol 2007;45: 237-40.
19. Hanekom M, Gey van Pittius NC, McEvoy C et al. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis 2011; 91: 510-23.
20. Warren RM, Victor TC, Streicher EM et al. Clonal expansion of a globally disseminated lineage of Mycobacterium tuberculosis with low IS6110 copy numbers. J Clin Microbiol 2004; 42: 5774-82.
21. Lau RWT, Ho P-L, Kao RYT et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother 2011; 55: 608-14.
22. Sirgel FA, Tait M,Warren RM et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 2011; doi:10.1089/mdr.2011.0063.
23. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press, 2000; 365-86. http://fokker.wi.mit.edu/primer3/ (5 January 2012, date last accessed).
24. Springer B, Lucke K, Calligaris-Maibach C et al. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-80.
25. Campbell PJ, Morlock GP, Sikes RD et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-41.
26. Böttger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-34.
27. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrobial Agents Chemother 2006; 50: 104-12.
28. Sun Z, Zhang J, Zhang X et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008; 31: 115-21.